• News
  • BioTech

BioAtla successfully engineers infection antibody

San Diego-based BioAtla, a global biotechnology company, and Telephus Medical LLC, a developer of vaccine products to prevent periprosthetic joint infections and accompanying osteomyelitis in orthopedic procedures, Tuesday announced that BioAtla has successfully completed a key protein engineering phase of Telephus' compound TPH 101.

TPH 101 is Telephus' lead program focused on the development of neutralizing antibodies targeting a key bacterial enzyme that drives the formation of antibiotic-resistant biofilm infections on implanted medical devices.

"We believe Telephus has created a significant franchise in the field for preventing drug-resistant biofilm infections," said Jay M. Short, Ph.D., president and chief executive officer of BioAtla. "This partnership is an ideal demonstration of the reliability and effectiveness of our proprietary platform to rapidly and efficiently generate optimized monoclonal antibodies for therapeutic development, including neutralizing antibodies for enzyme inhibition applications."

User Response
0 UserComments